Saturday 17 October 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.73
0.23
−11.73%
Follow PACB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 216.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 3 | 4 | 4 | 6 | 3 | 2 | 3 | 2 | 3 |
P/S ratio |
4.28 | 3.15 | 12.71 | 8.63 | 54.31 | 32.00 | 13.90 | 12.13 | 3.26 | 3.51 |
Altman Z-Score |
(4.57) | (6.46) | 1.84 | (6.40) | 29.53 | 1.55 | (0.40) | (0.12) | (2.70) | (6.04) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 232.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(16.84) | (19.21) | (16.62) | (26.02) | (0.35) | 1.36 | (1.32) | (1.59) | (5.15) | (13.42) |
Beneish M-Score |
(1.38) | (3.18) | (3.79) | 0.72 | (2.35) | (1.00) | (2.83) | (1.48) | (3.16) | (5.14) |
P/Operating CF |
(30.13) | (14.60) | (52.66) | (43.12) | (300.42) | (131.72) | (29.44) | (42.26) | (16.39) | (29.42) |
P/B ratio |
4.59 | 3.42 | 8.76 | 14.28 | 12.77 | 5.28 | 3.17 | 3.47 | 0.99 | 104.86 |
Price to Tangible BV |
4.59 | 3.42 | 8.76 | 14.28 | 12.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.67 | 2.63 | 11.60 | 8.54 | 50.74 | 30.86 | 14.86 | 13.43 | 4.93 | 5.79 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.90) | (3.64) | (13.73) | (9.92) | 205.27 | (36.23) | (7.25) | (10.39) | (3.68) | (8.33) |
EV/FCF |
(4.37) | (3.15) | (13.36) | (9.57) | 216.82 | (34.39) | (6.81) | (10.05) | (3.58) | (7.79) |
Quick Ratio |
2.47 | 2.66 | 4.13 | 1.32 | 8.74 | 14.91 | 3.01 | 7.03 | 6.31 | 4.32 |
Current Ratio |
3.23 | 3.55 | 4.90 | 1.65 | 9.24 | 15.36 | 3.24 | 7.81 | 7.48 | 5.15 |
Net Debt/EBITDA |
0.84 | 0.61 | 0.94 | 0.08 | 2.96 | 0.76 | (0.43) | (0.81) | (1.03) | (2.33) |
Debt/Assets |
11.68% | 9.46% | 8.61% | 28.38% | 9.18% | 44.65% | 50.74% | 51.10% | 51.37% | 82.31% |
Debt/Equity |
0.19 | 0.16 | 0.13 | 0.76 | 0.11 | 1.13 | 1.59 | 1.27 | 1.28 | 120.65 |
Asset Turnover |
0.67 | 0.66 | 0.50 | 0.57 | 0.28 | 0.11 | 0.07 | 0.11 | 0.10 | 0.16 |
Operating CF/Net income |
0.91 | 0.73 | 0.65 | 0.93 | 0.66 | 0.61 | 0.84 | 0.84 | 0.67 | 0.20 |
Capex/Depreciation |
(1.63) | (1.08) | (0.25) | (0.28) | (0.11) | (0.38) | (0.99) | (0.65) | (0.03) | (0.02) |
Interest Coverage |
(22.03) | (30.74) | (41.68) | (38.51) | (390.96) | (16.79) | (20.91) | (23.32) | (35.36) | (79.65) |
| (94.02%) | (107.97%) | (102.48%) | (99.58%) | 15.06% | (32.18%) | (46.42%) | (48.53%) | (51.30%) | (213.45%) | |
| (55.30%) | (65.39%) | (65.25%) | (52.87%) | 10.46% | (14.97%) | (16.65%) | (17.46%) | (20.61%) | (53.45%) | |
ROIC |
(154.63%) | (152.21%) | (239.39%) | (132.25%) | (121.17%) | (20.48%) | (27.95%) | (21.73%) | (38.83%) | (93.25%) |
Return on Tangible Assets |
(82.83%) | (83.13%) | (73.87%) | (135.78%) | 8.60% | (17.07%) | (49.86%) | (44.88%) | (67.38%) | (167.41%) |
Average Days of Receivables |
45.95 | 52.46 | 39.90 | 61.31 | 77.90 | 67.79 | 53.44 | 66.65 | 65.23 | 80.86 |
Research and Development Expense of Revenue |
74.54% | 69.89% | 79.61% | 65.61% | 81.32% | 86.50% | 150.42% | 93.34% | 87.60% | 60.81% |
Selling, General and Administrative Expense of Revenue |
52.68% | 63.25% | 80.75% | 83.06% | 92.28% | 95.10% | 125.37% | 84.69% | 113.64% | 88.43% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.46 | 0.53 | 0.56 | 0.42 |
Share Based Compensation of Revenue |
21.56% | 21.77% | 29.45% | 18.04% | 22.22% | 56.21% | 61.27% | 35.97% | 46.12% | 26.04% |
Graham Net Nets |
0.14 | 0.15 | 0.08 | (0.02) | 0.06 | (0.03) | (0.20) | (0.12) | (0.51) | (0.72) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 2.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(19.27%) | (31.90%) | (10.41%) | (10.70%) | 0.46% | (4.35%) | (17.63%) | (12.62%) | (62.30%) | (98.40%) |
Free Cash Flow Yield |
(19.59%) | (26.42%) | (6.83%) | (10.35%) | 0.43% | (2.80%) | (15.70%) | (11.02%) | (42.25%) | (21.20%) |
Revenue per Share |
1.02 | 0.88 | 0.58 | 0.60 | 0.48 | 0.64 | 0.57 | 0.79 | 0.56 | 0.53 |
Operating CF per Share |
(0.76) | (0.64) | (0.49) | (0.51) | 0.12 | (0.54) | (1.17) | (1.02) | (0.75) | (0.37) |
Capex per Share |
(0.09) | (0.10) | (0.01) | (0.02) | (0.01) | (0.03) | (0.08) | (0.03) | (0.02) | (0.03) |
Free Cash Flow per Share |
(0.85) | (0.74) | (0.51) | (0.53) | 0.11 | (0.57) | (1.25) | (1.06) | (0.77) | (0.40) |
Cash per Share |
0.81 | 0.59 | 0.76 | 0.32 | 1.94 | 5.12 | 3.44 | 2.49 | 1.42 | 0.93 |
Shareholders Equity per Share |
0.95 | 0.81 | 0.84 | 0.36 | 2.03 | 3.87 | 2.51 | 2.77 | 1.85 | 0.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.95 | 0.81 | 0.84 | 0.36 | 2.03 | 3.87 | 2.51 | 2.77 | 1.85 | 0.02 |
Free Cash Flow |
(76.13) | (77.91) | (68.28) | (81.15) | 18.46 | (117.11) | (280.14) | (268.02) | (212.25) | (118.92) |
Working Capital |
75.24 | 72.98 | 104.78 | 31.89 | 317.09 | 1,029.43 | 588.74 | 647.02 | 429.38 | 302.22 |
Capital Expenditures |
(8.20) | (10.39) | (1.85) | (2.84) | (1.04) | (5.93) | (16.93) | (8.84) | (6.19) | (7.71) |
Net Current Asset Value |
55.80 | 43.64 | 75.45 | (12.02) | 277.10 | (114.85) | (352.11) | (302.66) | (258.17) | (403.68) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.09 | 0.11 | 0.02 | 0.03 | 0.01 | 0.05 | 0.13 | 0.04 | 0.04 | 0.05 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.25 | 0.22 | 0.34 | 0.37 | 0.48 | 0.41 | 0.38 | 7.37 | 16.44 |
Cash ROIC |
(44.07%) | (47.91%) | (29.55%) | (55.46%) | 2.66% | (4.29%) | (12.55%) | (12.04%) | (13.74%) | (12.78%) |
Accounts Receivable Turnover |
10.89 | 7.52 | 7.14 | 7.62 | 4.92 | 6.35 | 5.96 | 7.24 | 4.80 | 5.08 |
Accounts Payable Turnover |
7.10 | 6.74 | 6.76 | 7.46 | 7.76 | 9.83 | 6.88 | 10.91 | 7.38 | 6.11 |
Inventory Turnover |
3.50 | 3.04 | 2.61 | 3.61 | 3.36 | 3.69 | 2.11 | 2.76 | 2.02 | 2.11 |
Average Days of Payables |
65.54 | 56.44 | 45.93 | 54.24 | 28.20 | 56.04 | 55.38 | 37.21 | 51.87 | 66.37 |
Days of Inventory on Hand |
122.58 | 143.15 | 121.90 | 86.28 | 112.12 | 125.31 | 231.98 | 140.02 | 183.72 | 157.49 |
Average Receivables |
8.33 | 12.43 | 11.01 | 11.93 | 16.05 | 20.54 | 21.51 | 27.70 | 32.07 | 31.49 |
Average Payables |
6.55 | 8.73 | 7.91 | 7.55 | 5.97 | 7.29 | 11.52 | 13.55 | 15.83 | 18.68 |
Average Inventory |
13.29 | 19.35 | 20.47 | 15.60 | 13.77 | 19.41 | 37.49 | 53.53 | 57.72 | 54.02 |
Average Assets |
134.50 | 140.98 | 157.18 | 159.13 | 280.98 | 1,210.48 | 1,887.03 | 1,756.55 | 1,503.23 | 1,022.27 |
Average Common Equity |
79.10 | 85.39 | 100.08 | 84.49 | 195.20 | 563.24 | 676.95 | 632.10 | 603.95 | 255.97 |
Columns are period end dates